In parallel, they overexpressed pro-angiogenic markers such as ANGPT2 and PKM2 (Figure 5F,G), suggesting tumor hyper-vascularization [27], which is the primary target of the anti-angiogenic agent sorafenib. This evidence concerns the gene PKM and neoplasm.